Kongressdetails

Elayda Hearne

The potential to target the inflammasome as a therapeutic for many diseases is huge, with rapid advances and excitement in the field, now is the time combine forces and help accelerate development of truly curative inflammasome therapeutics.

The inaugural Inflammasome Therapeutics Summit (ITS) is industry's first dedicated discussion and networking forum focused on bringing together inflammasome thought-leaders to share the latest scientific progress and address the current challenges drug developers are facing. With the mission to bridge the gap between research and drug development and develop clinically effective candidates for inflammatory driven diseases.

Join 60 of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from over 19 expert speakers on latest developments, sharing insights and science to elevate clinically effective inflammasome therapeutic pipelines.

Developed in combination with experts from Nodthera, Pfizer and IFM Therapeutics and other leading organisations, this industry focused forum allows you to determine which diseases the inflammasome is driving and therefore which have the most therapeutic potential commercially and clinically, review the basic biology and mechanisms of action and the use of biomarkers and endpoints for increased efficacy in clinical trials to name a few.

Leave ITS with a deeper understanding of the discovery, preclinical and clinical landscape of inflammasome therapeutics.